Zanubrutinib
Ibrutinib Plus Bendamustine and Rituximab
Polatuzumab Vedotin-piiq
COVID-19 and Aggressive Lymphoma: Frequently Asked Questions Answered by ASH
National Cancer Institute: Lymphoma—Patient Version
JNCCN: How to Manage Cancer Care During COVID-19 Pandemic
National Comprehensive Cancer Network